Experience

Davis Polk advised Morgan Stanley on the recommencement of its SEC-registered financing programs and the related filing of its universal shelf registration statement, which includes a…

Davis Polk advised the sole underwriter in connection with a block trade of 10,000,000 common shares of Genpact Limited by funds affiliated with Bain Capital Investors, LLC and its co…

Davis Polk is advising J.P. Morgan Securities LLC as financial adviser to Cavium, Inc. in connection with its $6 billion acquisition by Marvell Technology Group Ltd. The transaction is…

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Rambus Inc. of $172.5 million aggregate principal amount of its 1.375%…

Davis Polk advised Banco Bilbao Vizcaya Argentaria, S.A. on its SEC-registered offering of $1 billion liquidation preference of non-step-up, non-cumulative contingent convertible perpetual…

Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A offering by Quotient Technology Inc. of $175 million aggregate principal amount of its 1…

Davis Polk advised the book-running managers and the representatives of the several underwriters in connection with the initial public offering by SendGrid, Inc. of 9,430,000 shares of…

Davis Polk advised the initial purchaser of a Rule 144A/Regulation S offering by Torchmark Corporation of $125 million aggregate principal amount of 5.275% junior subordinated…

Davis Polk advised the underwriters of an $805 million SEC-registered offering of 6,440,000 shares of common stock of Alnylam Pharmaceuticals, Inc. Included in the shares are 840,000…

Davis Polk advised Roche Holdings, Inc. as to U.S. law in connection with its cash tender offer for up to €250 million aggregate principal amount of its 6.50% notes due 2021. Headquartered…